close

Fenwick Represents NeuroVision in $15 Million Series C Financing

May 02, 2018

Fenwick & West represented NeuroVision Imaging Inc., a leading developer of digital imaging and diagnostic solutions for identifying retinal pathology related to Alzheimer’s Disease (AD), in its $15 million Series C financing. Wildcat Capital Management led the round with participation from several new investment groups, including Johnson & Johnson Innovation - JJDC, Nikon-SBI Innovation Fund, Whittier Ventures LLC and VSP Global.

The financing provides support for NeuroVision as the company seeks validation and regulatory approval for its low-cost, noninvasive eye imaging system for measuring retinal autofluorescence that can detect amyloid beta (Aβ) plaque in the eye. More information regarding NeuroVision’s $15 million Series C financing can be obtained from the company announcement.

The Fenwick transaction team was led by corporate lawyers Ian Goldstein and Shen Zhang.